MET and gastric cancer: Onartuzumab and rilotumumab, which target MET and MET-ligand HGF, respectively, have been used in phase III trials as first-line treatment in combination with conventional chemotherapy but failed to improve the clinical outcome of GC patients with MET overexpression [95,96].